BioPorto Valuation

Is THOX.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of THOX.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate THOX.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate THOX.F's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for THOX.F?

Key metric: As THOX.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for THOX.F. This is calculated by dividing THOX.F's market cap by their current revenue.
What is THOX.F's PS Ratio?
PS Ratio	24.5x
Sales	DKK 33.83m
Market Cap	DKK 828.38m

THOX.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	21.6x
Enterprise Value/EBITDA	-13.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does THOX.F's PS Ratio compare to its peers?

The above table shows the PS ratio for THOX.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	17.1x
PLX Protalix BioTherapeutics	2.7x	58.9%	US$103.0m
TLSI TriSalus Life Sciences	4.2x	33.6%	US$119.8m
IPSC Century Therapeutics	39.6x	18.6%	US$103.7m
ANL Adlai Nortye	21.8x	65.7%	US$115.1m
THOX.F BioPorto	24.5x	29.2%	US$828.4m

Price-To-Sales vs Peers: THOX.F is expensive based on its Price-To-Sales Ratio (24.5x) compared to the peer average (2.3x).

Price to Sales Ratio vs Industry

How does THOX.F's PS Ratio compare vs other companies in the US Biotechs Industry?

145 Companies	Price / Sales	Estimated Growth	Market Cap
AMGN Amgen	4.6x	2.4%	US$152.45b
GILD Gilead Sciences	3.9x	2.4%	US$110.17b
BIIB Biogen	2.4x	1.3%	US$23.31b
INCY Incyte	3.6x	8.9%	US$14.62b

145 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: THOX.F is expensive based on its Price-To-Sales Ratio (24.5x) compared to the US Biotechs industry average (12x).

Price to Sales Ratio vs Fair Ratio

What is THOX.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

THOX.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	24.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate THOX.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Collegium Pharmaceutical

US$954.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$29.22

-9.2%

14.2%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.25

-10.5%

7.7%

Teva Pharmaceutical Industries

US$18.6b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.49

-5.1%

74.5%